We previously showed that Qiliqiangxin (QL) capsules could ameliorate cardiac hypertrophy and remodeling in a mouse model of pressure overload. Here, we compared the effects of QL alone with those of QL combined with the following 3 types of antihypertensive drugs on cardiac remodeling and dysfunction induced by pressure overload for 4 weeks in mice: an angiotensin II type 1 receptor (AT 1 -R) blocker (ARB), an angiotensin-converting enzyme inhibitor (ACEI), and a b-adrenergic receptor (b-AR) blocker (BB). Adult male mice (C57B/L6) were subjected to either transverse aortic constriction or sham operation for 4 weeks, and the drugs (or saline) were orally administered through gastric tubes. Cardiac function and remodeling were evaluated through echocardiography, catheterization, histology, and analysis of hypertrophic gene expression. Cardiomyocyte apoptosis and autophagy, AT 1 -R and b 1 -AR expression, and cell proliferation-related molecules were also examined. Although pressure overload-induced cardiac remodeling and dysfunction, hypertrophic gene reprogramming, AT 1 -R and b 1 -AR expression, and ERK phosphorylation were significantly attenuated by QL alone, QL + ARB, QL + ACEI, and QL + BB, the attenuation was stronger in the combination treatment groups. Moreover, apoptosis was reduced to a larger extent by each combination treatment than by QL alone, whereas autophagy was more strongly attenuated by either QL + ARB or QL + ACEI. None of the treatments significantly upregulated ErbB2 or ErbB4 phosphorylation, and none significantly downregulated C/EBPb expression. Therefore, the effects of QL on chronic pressure overload-induced cardiac remodeling may be significantly increased when QL is combined with an ARB, an ACEI, or a BB.
INTRODUCTION
Hypertension, which is one of the most common causes of heart failure, reportedly leads to the development of cardiac hypertrophy, which ultimately progresses to heart failure. 1, 2 Chronic pressure overload-induced adaptive cardiac hypertrophy is initially characterized by a thickened ventricular wall and by enhanced left ventricular systolic function. Excessive activation of the renin-angiotensin-aldosterone system and other neuroendocrine systems, as well as the release of angiotensin II (Ang II) and catecholamines, results in the development of irreversible chronic heart failure. 3, 4 Despite significant improvements in the understanding of this disease, as well as the effort expended to treat it, the prognosis of heart failure continues to be poor. 5, 6 Qiliqiangxin (QL) capsules contain a specific traditional Chinese medicine formulation that includes extracts from 11 types of herbs, including Radix Astragali, aconite root, Salvia miltiorrhiza, Ginseng, Semen Lepidii Apetali, Carthamus tinctorius, Cortex Periplocae Sepii Radicis, Rhizoma Alismatis, seasoned orange peel, Polygonatum Odorati, and Rumulus Ginnamomi, based on the meridian theory. Radix astragali is the principal active pharmacological component. 7 QL has been demonstrated to be both a safe and efficient treatment for heart failure in both animal models and clinical trials. [7] [8] [9] [10] In 2004, QL capsules were approved by the Chinese Food and Drug Administration for the treatment of patients with heart failure. Our previous study demonstrated that QL suppressed myocardial inflammation, cardiomyocyte apoptosis, and autophagy while promoting cardiomyocyte proliferation, which resulted in the amelioration of pressure overload-induced cardiac remodeling and cardiac dysfunction. 11 Other studies have revealed that QL may improve cardiac dysfunction in spontaneous hypertensive rats by inhibiting the cardiac chymase signaling pathway and that QL may have antiarrhythmic properties that enable it to regulate L-type Ca currents, Na currents, and K currents in rat ventricular myocytes. 8, 12 According to the 2013 AHA guidelines for the management of heart failure, diuretics, angiotensinconverting enzyme inhibitors (ACEIs), ARBs, betablockers, aldosterone receptor antagonists, and other agents are recommended as standard therapies for chronic heart failure. 1 However, it is not clear whether combining these drugs with QL can enhance its effects on chronic heart failure. Recently, a multicenter, randomized, double-blind and placebo-controlled study revealed that QL further decreased the level of NT-proBNP in patients with chronic heart failure when used together with standard therapy. These results suggest that QL in combination with standard therapy may represent an improved means of treating chronic heart failure. 7 In this study, we treated mice suffering from pressure overload with either QL alone or with QL in combination with olmesartan (ARB), captopril (ACEI) or metoprolol (BB), as each of these drugs is widely prescribed in clinical practice to treat chronic heart failure. [13] [14] [15] We aimed to determine whether QL combined with these antihypertensive agents exerted superior cardioprotective effects compared with QL alone in the setting of chronic pressure overload-induced cardiac remodeling. We also attempted to determine whether the suppression of cardiomyocyte apoptosis and autophagy as well as the upregulation of cardiomyocyte proliferation as a result of QL treatment were affected by the use of the 3 aforementioned classes of drugs.
MATERIALS AND METHODS

Animal Models
C57BL/6 male mice (Shanghai Laboratory Animal Center, Chinese Academy of Sciences, Shanghai, China) that were aged 8-10 weeks were anesthetized and underwent either a transverse aortic constriction (TAC) or a sham operation, as previously described. 16, 17 In brief, after anesthetization, the transverse aorta was constricted with a 7-0 nylon suture by ligating the aorta together with a blunted 27-gauge needle, which was later removed. The animal experimental protocols were carried out in compliance with the Guidelines for the Care and Use of Laboratory Animals (published by the National Academy Press: National Institutes of Health Publication No. 85-23, revised 1996) and approved by the Animal Care and Use Committee of Fudan University.
Administration of Drugs
All drugs, including Qiliqiangxin (Shijiazhuang Yiling Pharmaceutical, Shijiazhuang, China), olmesartan (Daiichi Sankyo Pharmaceutical, Shanghai, China), captopril (BristolMyers Squibb, Shanghai, China), and metoprolol (AstraZeneca Pharmaceutical, Shanghai, China), were purchased commercially.
The mice were randomly divided into the following 6 groups: the Sham group (n = 7), the TAC group (n = 7), the QL group (n = 7), the QL + olmesartan group (n = 7), the QL + captopril group (n = 7), and the QL + metoprolol group (n = 7). Each of the drugs was dissolved in distilled water, and equal volumes of freshly prepared solution or distilled water (0.2 mL) were administered to mice daily through a gastric tube for 4 weeks. The dosages of QL, olmesartan, captopril, and metoprolol were 0.6, 5.4, 10, and 30 mg$kg$ 21 d$ 21 , respectively. The dosage chosen for each drug was based on clinically relevant concentrations and previously published data. [18] [19] [20] 
Echocardiography and Hemodynamic Measurements
Transthoracic echocardiography was performed using a 30-MHz high-frequency scan head (VisualSonics Vevo770; VisualSonics, Toronto, Canada). The mice were anesthetized with a mixture of isoflurane (2%) and oxygen (2 L/min). All measurements were averaged over 5 consecutive cardiac cycles and were carried out by 3 technicians who were blinded to the experimental group identities. Aortic blood pressure (ABP) was evaluated as described. 18 In brief, a micro-nanometer catheter (Millar 1.4F, SPR 835; Millar Instruments, Inc, Houston, TX) was inserted into the right common carotid artery and ultimately introduced into the LV, and the transducer was connected to a Power Laboratory system (AD Instruments, Castle Hill, Australia) to record ABP, LV end-systolic pressure, LV end-diastolic pressure, and dP/dT.
Morphological and Histological Analyses
The mice were killed, and the hearts were excised at 4 weeks after TAC. The excised hearts were weighed, perfused with PBS, and fixed with 4% polyformaldehyde for global morphometry before being embedded in paraffin or frozen in liquid nitrogen for further histological analysis. The paraffinembedded hearts were sectioned at a thickness of 4 mm and stained with either hematoxylin and eosin (H&E) or Masson's trichrome. For measurements, 5 random high-power fields from each section were chosen and quantified in a blinded manner. The cross-sectional area (CSA) of the cardiomyocytes was analyzed quantitatively through morphometric analysis of the H&E-stained sections. The extent of the fibrosis was evaluated by measuring the Masson's trichrome-stained area within the entire LV wall. Five sections of each heart were examined. The images were measured using an automated image analysis system (Image-Pro Plus 5.0; Media Cybernetics, Rockville, MD).
Real-time RT-PCR
Total RNA was extracted from the heart tissues using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions, and reverse-transcription-polymerase chain reaction (RT-PCR) was performed using a TOYOBO RT-PCR kit. After purification, real-time RT-PCR analysis of the expression of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), skeletal a-actin (SAA), and sarcoplasmic reticulum Ca2+ adenosine triphosphatase (SERCA2a) was performed using a Bio-RAD IQ5 multicolor detection system (all the primers are listed in Table 1 ). The melting curves and quantification were analyzed using Bio-RAD software. The comparative cycle threshold method was used to determine the relative RNA expression levels. Each of the PCRs was repeated at least 3 times.
Western Blot Analysis
Total proteins isolated from the heart tissues were size fractionated using SDS-PAGE and transferred onto Immobilon-P membranes (Millipore, Billerica, MA). The blotted membranes were incubated with antibodies against p-ERK, t-ERK, p-ErbB2, p-ErbB4, LC3b (Cell Signaling Technology, Beverly, MA), b 1 -AR (beta-1 adrenergic receptor; Abcam, Cambridge, MA), C/EBPb, and AT 1 -R, (Santa Cruz Biotechnology Inc, Santa Cruz, CA) and with an HRP-conjugated secondary antibody (1:5000, KangChen Biotechnology, Shanghai, China). Either GAPDH or t-ERK was used as an internal control. The proteins were visualized using an ECL Western blotting detection system (GE Healthcare, catalog number RPN2106). The relative intensities of the protein bands were analyzed through densitometry with a gel documentation system using LAS-300 image analysis software. All experiments were repeated at least 3 times. 
Apoptotic Cell Analysis by TUNEL Labeling
Statistical Analysis
All data are expressed as the mean 6 standard errors of the mean. Group mean values were compared by 1-way analysis of variance followed by an least significant difference (LSD) test. Comparisons between 2 groups were conducted using a 2-tailed Student's t test. A value of P , 0.05 was considered statistically significant.
RESULTS
Effects of QL Alone or QL in Combination With Olmesartan, Captopril, or Metoprolol on the Hemodynamic Parameters and Cardiac Function of Mice Suffering From Pressure Overload
Four weeks of TAC induced cardiac remodeling characterized by reduced cardiac contractility and a reduced ejection fraction. We investigated the improvements in cardiac remodeling induced by either QL alone or by QL in combination with olmesartan (QL + olm), captopril (QL + cap), or metoprolol (QL + met) at 4 weeks after the TAC operation. As expected, TAC induced an obvious increase in ABP, left ventricular end-systolic pressure, and left ventricular end-diastolic pressure based on the results of hemodynamic analysis. QL, QL + olm, QL + cap, and QL + met did not affect ABP or left ventricular end-systolic pressure after TAC but significantly attenuated the elevation of left ventricular end-diastolic pressure induced by TAC (Fig. 1A and see Figure 1 , Supplemental Digital Content, http://links.lww.com/JCVP/A180). Both +dp/dt max and 2dp/dt max , indices of cardiomyocyte contractility, were significantly decreased by TAC; QL induced significant increases in +dp/dt max and 2dp/dt max after TAC. QL + olm, QL + cap, and QL + met induced higher + dp/dt max and 2dp/dt max values than QL alone after TAC (Fig. 1B and see Figure 2 , Supplemental Digital Content, http://links.lww.com/JCVP/A180). An echocardiographic analysis indicated that 4 weeks of TAC resulted in a significantly decreased left ventricular ejection fraction; QL significantly attenuated this effect, and olm, cap, and met amplified the protective effect exerted by QL (Table 2 ). However, there was no difference in these effects among the QL + olm, QL + cap, or QL + met groups. These data indicated that QL in combination with olmesartan, captopril, or metoprolol had superior protective effects on cardiac contractility and cardiac function compared with QL alone under similar pressure overload conditions. Maladaptive cardiac hypertrophy results in heart failure in the setting of pressure overload. 21 In this study, TAC induced cardiac hypertrophy characterized by an elevated heart weight-to-body weight ratio, increased cardiomyocyte CSA, increased LV anterior wall thickness during end-diastole, and decreased LV posterior wall thickness during end systole. QL greatly attenuated these effects; QL + olm, QL + cap, or QL + met inhibited the aforementioned hypertrophic responses to a larger extent than QL alone after TAC. Masson's trichrome staining indicated that QL reduced the fibrotic areas induced by TAC. QL + olm, QL + cap, and QL + met treatments resulted in significant decreases in fibrotic areas compared with QL alone (Figs. 2A, B) . In addition, we investigated the expression of hypertrophic genes, such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), skeleton a-actin (SAA), and sarcoplasmic reticulum Ca 2+ adenosine triphosphatase 2 (SERCA2) in heart tissue. Pressure overload resulted in the significant upregulation of ANP, BNP, and SAA gene expression and downregulation of SERCA2 gene expression; these effects were partially abolished in the QL group and in the combination therapy groups. QL + olm, QL + cap, and QL + met demonstrated superior inhibitory effects on the expression of the hypertrophic genes compared with QL alone. There was no significant difference among the QL + olm, QL + cap, or QL + met groups in terms of their effects on hypertrophic gene expression (Fig. 2C) . These results indicated that QL in combination with olmesartan, captopril, or metoprolol exerted stronger inhibitory effects on cardiac hypertrophy than QL alone. This finding indicates that combination therapy may result in improvements in cardiac function that are superior to those induced by treatment with QL alone in the setting of heart failure induced by pressure overload.
Inhibitory Effects of QL
It has been demonstrated that cardiomyocyte apoptosis and autophagy are required for the transition from compensated cardiac hypertrophy to heart failure. [21] [22] [23] [24] Therefore, we examined the effects of QL and combination therapy on each of these cellular processes using TUNEL labeling and immunofluorescence staining. After 4 weeks, chronic pressure overload induced larger numbers of TUNEL-positive cells and LC3b-positive cells in the heart based on the results of the immunostaining analysis (Figs. 3A, B) . The results of a Western blot were consistent with the LC3b expression levels in heart tissue. Treatment with QL significantly attenuated TAC-induced cardiac apoptosis and autophagy. QL + olm, QL + cap, and QL + met decreased the numbers of TUNEL-positive cells, and QL + olm and QL + cap decreased the numbers of LC3B-positive cells and decreased the level of LC3b expression in heart tissue to a larger extent than QL alone (Fig. 3C) .
These results suggested that QL in combination with olmesartan, captopril, or metoprolol exerted greater inhibitory effects on cardiac apoptosis and autophagy compared with QL alone. TAC. QL + olm and QL + cap induced responses similar to QL treatment alone, and these treatments exerted similar effects on the expression of b 1 -AR; however, QL + olm and QL + cap reduced the expression level of AT 1 -R in the myocardium to a greater extent than QL alone. In addition, QL + met reduced the expression of b 1 -AR to a greater extent than QL alone; however, QL + met and QL inhibited the expression of AT 1 -R to a similar extent. The activation of either AT 1 -R or b 1 -AR induced the phosphorylation of ERK (p-ERK), which contributes to the hypertrophic response commonly observed in the setting of pressure overload. 25, 26 QL significantly suppressed the upregulation of p-ERK that was induced by TAC; QL + olm, QL + cap, and QL + met enhanced the inhibitory effect exerted by QL on the TAC-induced upregulation of p-ERK. There was no significant difference among the QL + olm, QL + cap, or QL + met groups in terms of their effects on the abovementioned processes (Fig. 4) .
The addition of olmesartan, captopril, or metoprolol to QL enhances the effects exerted by QL alone on pressure overload-induced cardiac dysfunction.
Effects of QL Alone or QL in Combination
With Olmesartan, Captopril, or Metoprolol on Cardiomyocyte Proliferation After TAC Our previously published data indicated that ErbB family receptors and C/EBPb may be involved in the effects of QL on cardiac remodeling and subsequent cardiac dysfunction. 11 Four weeks of TAC exerted only limited effects on the expression of p-ErbB2, p-ErbB4, and C/EBPb compared with the sham group (Fig. 5A) . QL alone or in combination with olmesartan, captopril, or metoprolol upregulated the expression of both p-ErbB2 and p-ErbB4 and downregulated the expression of C/EBPb compared with TAC. QL + olm and QL + cap treatment resulted in a higher p-ErbB2 expression level, and QL + cap and QL + met induced an increase in p-ErbB4 expression that was greater than the increase facilitated by QL alone, although this difference was not statistically significant. We then determined the numbers of Ki67-positive cardiomyocytes in the myocardium through double immunostaining methods (Ki67 is an index of proliferation). There were only limited numbers of Ki67-positive cardiomyocytes in both the sham and TAC groups. Both QL alone and QL in combination with olmesartan, captopril, or metoprolol increased the number of Ki67-positive cardiomyocytes in the myocardium after TAC. However, there was no significant difference among the QL, QL + olm, QL + cap, or QL + met groups (Fig. 5B) .
These results suggested that QL alone and QL in combination with olmesartan, captopril, or metoprolol induced cardiomyocyte proliferation after TAC. However, the increases in cardiomyocyte proliferation noted among these groups were not significantly different.
DISCUSSION
This study has demonstrated both the safety and the efficacy of QL combination therapy with an ARB (olmesartan), FIGURE 5 . Effects of QL alone or in combination with olmesartan, captopril, or metoprolol on cardiomyocyte proliferation duringan ACEI (captopril), and a BB (metoprolol) in the treatment of chronic pressure overload-induced cardiac hypertrophy in mice. Combination therapy exhibited superior protective effects on cardiac remodeling and dysfunction compared with QL treatment alone. Mechanistically, cardiomyocyte apoptosis was reduced to a larger extent by each of the combination treatments, whereas autophagy was attenuated more significantly by the combination of QL with either an ARB or an ACEI, but not by the combination of QL with a BB. In addition, the expression levels of AT 1 -R and b 1 -AR were downregulated more significantly by the combination of QL with either an ARB or an ACEI as well as by the combination of QL with a BB. However, the increase in cardiomyocyte proliferation was not significantly different among the QL, QL + ARB, QL + ACEI, and QL + BB groups.
The AngII/AT 1 -R system plays a pivotal role in the progression of cardiac hypertrophy and the development of heart failure. [27] [28] [29] Blocking the generation of AngII or the activation of AT 1 -R with a renin inhibitor, an ACEI, or an ARB ameliorates cardiac remodeling and dysfunction. [30] [31] [32] However, therapeutic approaches that involve the combination of an ACEI with an ARB remain controversial. The combination of an ACEI and an ARB did not significantly improve the morbidity and mortality of cerebrovascular disease or congestive heart failure in the CHARM-Added trial, 33 However, in the ONTARGET trial, the combination of the 2 therapies worsened renal function compared with the use of an ACEI or an ARB alone. 34 This finding suggests that significant risk may be associated with this form of combination therapy. Interestingly, in this study, QL in combination with either olmesartan or captopril improved the cardiac dysfunction induced by pressure overload. Recently, QL reportedly facilitated decreases in the level of NTproBNP in patients with chronic heart failure as a result of treatment with an ARB or an ACEI. These results suggest that QL in combination with either olmesartan or captopril may exert superior cardioprotective effects compared with an ARB or an ACEI. Metoprolol, one of the most commonly prescribed beta-blockers, exerts its pharmacological effects through the inhibition of adrenergic receptors. 35 Many largescale clinical trials, including the CIBISII, the MERIT-HF, and the COPERNICUS trial, have demonstrated that the long-term use of a BB in patients with heart failure reduces overall mortality, cardiovascular mortality, and the risk of sudden cardiac death. 36 During the early phase of pressure overload, adaptive cardiac hypertrophy is beneficial because it enables the heart to retain its normal level of function. However, excessive cardiac hypertrophy and fibrosis lead to irreversible heart failure during late-phase pressure overload. 21 In this study, QL in combination with olmesartan, captopril, or metoprolol had a significant inhibitory effect on cardiac hypertrophy and fibrosis in mice in the setting of pressure overload. This effect was greater than that exerted by QL alone and was characterized by decreases in the heart weight-to-body weight ratio, cardiomyocyte CSA, expression of hypertrophic genes, and fibrosis area. These findings may partially explain why QL combined with metoprolol may be more effective for treating patients with heart failure. Autophagy and apoptosis are 2 self-destructive processes that play an important role in the maintenance of cardiac function in the pathogenesis of heart failure. 21, 37, 38 The crosstalk between these 2 process was only partially uncovered. A number of studies have confirmed that a variety of common upstream stimuli (including pressure overload) can trigger both autophagy and apoptosis. 17 Notably, autophagy is a lysosomal degradation procedure, which can be beneficial or detrimental. Mostly, autophagy makes cells to adapt to stress, but massive autophagy can also induce cell death. 39 Comparably, apoptosis is a process of programmed cell death by which the targeted cells can be disposed by multicellular organisms. 37 Emerging data confirmed that autophagy and apoptosis could interact with each other regarding cell survival and death. 40 For example, ingredients of the apoptotic pathways can regulate autophagy process through crosstalk with autophagy-related proteins. 41 Similarly, activation of autophagy pathways can reduce apoptotic cell death during certain cellular stages. 42 In this study, we observed that pressure overload-induced autophagy and apoptosis of cardiomyocytes were significantly reduced at 4 weeks in the QL group, and cardiomyocyte apoptosis was reduced to a larger extent by each of the combination treatments than by QL alone, whereas autophagy was more strongly attenuated only in combination treatment with olmesartan or captopril. In our previous study, we revealed that autophagy induced by the pressure overload at 4 weeks in mice can be regulated by the AT 1 -R-mediated p38-MAPK pathway, 22 and the expression change of autophagy mark protein LC3b was similar with that of AT 1 -R in the combination groups. Thus, we inferred that the reasonable explanation for this result may be that treatment with metoprolol has no further influence on the expression of AT 1 -R, which can regulate the autophagy process induced by the pressure overload in mice. However, we still cannot exclude that the activation of AT 1 -R or b 1 -AR could affect the crosstalk between autophagy and apoptosis induced by pressure overload. Indeed, the relationship between these 2 processes seems extremely complex, and insights of the interconnections between the autophagy and apoptosis in the pathogenesis of heart failure induced by pressure overload are required for the further clarification of their common roles in heart failure and cardiac remodeling.
It has been demonstrated that pressure overload may trigger cardiac hypertrophy, fibrosis, apoptosis, or autophagy through the AT 1 -R-mediated ERK, JNK, or p38-MAPK pathways. 22 Beta-adrenergic receptors mediate these signaling pathways primarily through the cAMP/PKA or the ERK pathway. 43 In this study, the upregulation of AT 1 -R and b 1 -AR as a result of pressure overload was significantly inhibited by both QL and QL combination therapy. QL in combination with either olmesartan or captopril decreased the expression of AT 1 -R in the myocardium compared with QL alone; however, the effects of these combination treatments on b 1 -AR expression were similar to those of QL alone. QL in combination with metoprolol inhibited the upregulation of AT 1 -R, as did QL; however, the combination of the 2 agents both the hypertrophic response and to the fibrosis observed in the setting of pressure overload. 25, 26 In this study, QL significantly suppressed the upregulation of p-ERK induced by TAC, and QL in combination with olmesartan, captopril, or metoprolol decreased the level of p-ERK to a greater extent than QL alone. QL in combination with either olmesartan or captopril exerted an inhibitory effect on cardiac hypertrophy and fibrosis through the downregulation of both AT 1 -R expression and p-ERK levels, whereas QL in combination with metoprolol achieved similar results by inhibiting b 1 -AR expression and decreasing p-ERK levels.
Recently, some studies have demonstrated that cardiomyocytes have the potential to proliferate in response to specific stimuli, 44, 45 and ErbB receptors belong to the epidermal growth factor receptor family. 46 The binding of its agonist, Neuregulin1, to ErbB4 increases its kinase activity, induces heterodimerization with either ErbB2 or ErbB4, and stimulates intracellular signal transduction pathways 46 that contribute to myocardial regeneration. C/EBPb, a member of the bHLH family of DNA-binding transcription factors, plays a pivotal role in cell proliferation and differentiation in many tissues and cells, including cardiomyocytes. 47 The downregulation of cardiac C/EBPb levels curtailed the development of pressure overload-induced heart failure in mice. 45 Our results indicated that QL treatment increased the phosphorylation of both ErbB2 and ErbB4 and reduced the expression of C/EBPb compared with vehicle treatment in mice in the setting of pressure overload. However, combination therapy with olmesartan, captopril, and metoprolol did not cause any significant changes in the expression of these proteins compared with QL treatment, suggesting that the signaling pathway mediated by the AT 1 -R and the beta-adrenergic receptors exerted only a minimal effect on the cardiac regeneration signaling pathway mediated by the ErbB receptor and by CEBP/b at 4 weeks after TAC.
Our present study compared the effects of QL alone and QL combined with an ARB, an ACEI, or a BB on cardiac hypertrophy, remodeling, and dysfunction, each of which may be induced by chronic pressure overload. The results of our study indicated that combination therapy facilitated greater improvements in cardiac hypertrophy, fibrosis, and dysfunction, as well as cardiomyocyte apoptosis and autophagy, in the setting of pressure overload compared with QL alone, which may be indicative of the stronger cardioprotective role played by combination therapy. The mechanism underlying the effects of combination therapy may be related to the downregulation of AT 1 -R or b 1 -AR. In addition, both QL alone and combination therapy induced cardiomyocyte proliferation by regulating ErbB family receptors and CEBP/b in the setting of pressure overload; however, there was no difference in the effect exerted by QL alone and the effect exerted by QL in combination with olmesartan, captopril, or metoprolol. Although this study design does not fully reflect the complexity of QL's ability to treat heart failure in clinical practice, it has demonstrated that QL is both a safe and effective therapy for pressure overload-induced cardiac hypertrophy and remodeling in mice. However, the exact molecular mechanisms underlying the cardioprotective effects of QL remain unknown.
In conclusion, these results suggest that compared with QL alone, QL in combination with standard therapies may exert more beneficial effects in the setting of chronic pressure overload-induced cardiac hypertrophy, remodeling, and dysfunction.
